Datametrex 1copy(TM) COVID-19 qPCR Multi Kit Detects the Omicron Variant

0
267

Toronto, Ontario–(Newsfile Corp. – December 9, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that the 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”) which the Company has the rights to sell can detect the Omicron (B.1.1.529) variant.

The Omicron mutations do not affect the performance of the qPCR kit. COVID-19 testing and early detection and vaccines continue to offer protection against hospitalization and death and continue to play a critical role in controlling the COVID-19 pandemic.

“The company continues to work with our suppliers to provide a reliable and safe product that our consumers can rely on. With the new mutations of the COVID-19 virus being discovered worldwide including the new highly contagious Omicron variant, management feels that persistent COVID-19 testing will be necessary for the near future as part of the answer to keep people secure and healthy,” said Andrew Ryu, Chairman of the Company.

Also, the qPCR kit can detect COVID-19 regardless of the existence of SARS-CoV-2 variants and include the following variants:

  • UK variant (Alpha B.1.17)

  • South Africa variant (Beta P.1.351)

  • Brazil variant (Gamma P.1)

  • India variant (Delta B.1.617.2)

  • Columbia variant ( Mu B.1.621)

The qPCR kit is a nucleic test kit providing results in less than two hours and is a qualitative in vitro diagnostic (“IVD”) device test for simultaneous detection of RdRp, N, and E genes of SARS-CoV-2 via a nasopharyngeal swab and oropharyngeal swab. The kits are manufactured by 1drop Inc. (“1drop”) in South Korea.

About 1drop Inc.

1drop is located in Jungwon-gu, South Korea, and was incorporated in 2017 following a technology spin-off from Samsung Electronic’s C-Lab program. Samsung Electronic’s C-Lab, located in South Korea is an internal incubation program that first started in 2012 to help inspire a more creative company culture. 1drop already had more than five products approved in Europe in the past 18 months under the CE certification.

For more information please consult the website at: 1drop

The Company’s ability to fulfill any purchase order for COVID-19 test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for the COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis.

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain.

For additional information on Datametrex and other corporate information, please visit the Company’s website at www.datametrex.com.

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

###

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/107172